Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.54)
# 898
Out of 5,111 analysts
35
Total ratings
57.14%
Success rate
29.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $149.13 | - | 5 | May 15, 2025 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $3.87 | - | 4 | May 15, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $200.67 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $3.51 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint | Reiterates: Overweight | n/a | $16.93 | - | 6 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.48 | +35.14% | 2 | Aug 31, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $3.15 | +947.62% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $2.27 | +98.24% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.42 | +4,032.23% | 2 | May 17, 2022 |
Belite Bio
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $149.13
Upside: -
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.87
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $200.67
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.51
Upside: -
EyePoint
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.93
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.48
Upside: +35.14%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $3.15
Upside: +947.62%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.27
Upside: +98.24%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.42
Upside: +4,032.23%